reports
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
- Simon Brun
- ABGSC Energy Research
- John Olaisen
- Oliver Dunvold
- Stian Wibstad
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide an...
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s - BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, t...
- Jonathan Moreland
Diginex Limited Announces 57% Increase in Revenues and Transformed Bal...
Diginex Limited Announces 57% Increase in Revenues and Transformed Balance Sheet for Fiscal Year ended March 31, 2025 LONDON, July 11, 2025 (GLOBE NEWSWIRE) -- Diginex Limited (“Diginex” or the “Company”) (NASDAQ: DGNX), a leading provider of Sustainability RegTech solutions, today announced its financial results for the fiscal year ended March 31, 2025. Fiscal Year ended March 31, 2025 Full-Year Highlights: Revenues for the fiscal year ended March 31, 2025, increased 57% to $2.0 million driven primarily by an increase in software subscriptions and license fees.Net loss for the fisc...
First Bancshares, Inc. Announces Operating Results for Quarter Ended J...
First Bancshares, Inc. Announces Operating Results for Quarter Ended June 30, 2025 MOUNTAIN GROVE, Mo., July 11, 2025 (GLOBE NEWSWIRE) -- First Bancshares, Inc. (OTCQX: FBSI) (“Company”), the holding company for Stockmens Bank (“Bank”), today announced its unaudited financial results for the quarter ended June 30, 2025. For the second quarter of 2025, the Company reported after-tax net income of $1,824,000 or $0.75 per share-diluted compared to $1,630,000 or $0.67 per share-diluted for the same period in 2024. Net income for the second quarter of 2025 represents an after-tax return on ...
Moody's Ratings assigns Aaa and Aa1 to the Virginia Resources Authorit...
Moody's Ratings (Moody's) has assigned Aaa and Aa1 ratings to the Virginia Resources Authority's (VRA) Infrastructure and State Moral Obligation Revenue Bonds (Virginia Pooled Financing Program), Series 2025B. We have assigned Aaa ratings to the following sub-series: - $95.6 million Infrastructure R...
Moody's Ratings assigns Aaa and Aa1 to the Virginia Resources Authorit...
Moody's Ratings (Moody's) has assigned Aaa and Aa1 ratings to the Virginia Resources Authority's (VRA) Infrastructure and State Moral Obligation Revenue Bonds (Virginia Pooled Financing Program), Series 2025B. We have assigned Aaa ratings to the following sub-series: - $95.6 million Infrastructure...
Astera Labs Inc: 1 director
A director at Astera Labs Inc sold 18,264 shares at 101.524USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Akero Therapeutics Inc: 1 director
A director at Akero Therapeutics Inc sold 30,000 shares at 51.163USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Moody's Ratings assigns initial A3 issuer rating to DeSoto ISD, TX; as...
Moody's Ratings (Moody's) has assigned an initial A3 issuer rating to DeSoto Independent School District, TX. At the same time, we assigned A3 underlying and Aaa enhanced ratings to the district's approximately $193 million proposed Unlimited Tax School Building Bonds, Series 2025. Post-sale, the d...
GeneDx Holdings Corp: 2 directors
Two Directors at GeneDx Holdings Corp sold/sold after exercising options 8,498 shares at 93.000USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
BeOne Medicines Ltd: 1 director
A director at BeOne Medicines Ltd sold after exercising options/sold 49,395 shares at 18.827USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...
Rhythm Pharmaceuticals Inc: 4 directors
Four Directors at Rhythm Pharmaceuticals Inc sold after exercising options/sold 69,478 shares at between 77.130USD and 80.749USD. The significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trade...
Photronics Inc: 1 director
A director at Photronics Inc sold 15,000 shares at 19.970USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Krystal Biotech Inc: 2 directors
Two Directors at Krystal Biotech Inc sold 14,127 shares at between 150.263USD and 150.273USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
F3 Engages Resource Stock Digest
Kelowna, British Columbia--(Newsfile Corp. - July 11, 2025) - F3 Uranium Corp. (TSXV: FUU) (OTCQB: FUUFF) ("F3" or the "Company") announces that it has entered into a marketing services agreement (the "Agreement") with Resource Stock Digest ("RSD"), a company based out of Texas, effective July 21, 2025, pursuant to which, among other things, RSD has agreed to provide certain promotional services to the Company in accordance with Policy 3.4 - Investor Relations, Promotional and Market-Making Activities of the Exchange.RSD has been engaged for a 3-month advertising and marketing program for tota...
Atlassian Corp: 2 directors
Two Directors at Atlassian Corp sold 15,330 shares at between 204.747USD and 204.747USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
UiPath Inc: 1 director
A director at UiPath Inc sold 45,000 shares at 12.713USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Unity Software Inc: 1 director
A director at Unity Software Inc sold 50,000 shares at 30.010USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.